Search

Displaying results 701 - 710 of 3180 in total
  1. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted...

  2. Drug

    PF-06305591

    go.drugbank.com/drugs/DB12106
    Investigational

    Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).

  3. Drug

    PX-102

    go.drugbank.com/drugs/DB15416
    Investigational

    PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).

  4. Drug

    PF-05105679

    go.drugbank.com/drugs/DB15450
    Investigational

    PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).

  5. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. … N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.

    Synonyms: N,N′,N′′-tri-1,2-ethanediyl-, Phosphorothioic triamide, N,N′,N′′-tri-1,2-ethanediyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inhibitors
  6. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduc...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: Nb-atorvastatin, ATORVASTATINA P-CARE
  7. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alte...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Quaternium-18

    go.drugbank.com/drugs/DB11305
    ApprovedWithdrawn

    Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.

  9. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  10. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.